Systems, devices, and methods related to the individualized calibration and/or manufacturing of medical devices

Patent metadata

Field	Value
Publication number	US-12285251-B2
Application number	US-202117543633-A
Country	US
Kind code	B2
Filing date	Dec 6, 2021
Priority date	Aug 18, 2017
Publication date	Apr 29, 2025
Grant date	Apr 29, 2025

Abstract

Systems, devices, kits, and methods are provided herein in the form of example embodiments that relate to calibration of medical devices. The medical devices can be sensors adapted to sense a biochemical attribute. The embodiments can be used to determine calibration information specific to an individual medical device. The embodiments can determine the calibration information by reference to one or more parameters obtained during manufacturing of the medical device. The embodiments can also determine the calibration information by reference to in vitro testing of the medical devices. The embodiments also apply to systems incorporating those medical devices in their use in the field. Also described are embodiments of modifications to surfaces of sensor substrates, such as through applied radiation and/or the creation of a well, to aid in the placement and/or sizing of a sensor element on the substrate.

First claim

What is claimed is:

1. A continuous glucose monitoring system, comprising:
an in vivo sensor configured to generate a signal associated with a glucose level, wherein a first portion of the in vivo sensor is configured to be positioned beneath a skin surface of a user in the subcutaneous space and a second portion of the in vivo sensor is configured to remain outside the user; and
an on-skin sensor control unit, wherein the in vivo sensor is coupled to the sensor control unit and wherein the sensor control unit is programmed to process the generated signal from the in vivo sensor to generate a processed result that is representative of a glucose level of the user using calibration information, wherein the calibration information comprises a sensing characteristic of the in vivo sensor, and wherein the sensing characteristic is determined based at least in part on f 1 (RMP A ) and f 2 (RMP B );
wherein f 1 is a first nonlinear function of RMP A , and f 2 is a second nonlinear function of RMP B ; and
wherein RMP A is a first manufacturing parameter, and RMP B is a second manufacturing parameter.

2. The continuous glucose monitoring system of claim 1 , wherein the first manufacturing parameter affects a sensitivity of the in vivo sensor and the second manufacturing parameter affects the sensitivity of the in vivo sensor.

3. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprises a sensing region and the first manufacturing parameter comprises a size of the sensing region.

4. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a width of the sensing region.

5. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a length of the sensing region.

6. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a thickness of the sensing region.

7. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a peripheral length of the sensing region.

8. The continuous glucose monitoring system of claim 3 , wherein the size of the sensing region is representative of a volume of the sensing region.

9. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor is non-planar and comprises a working electrode and a counter electrode separated by non-conductive material.

10. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprises an analyte flux modulating membrane adjacent a sensing region.

11. The continuous glucose monitoring system of claim 10 , wherein the membrane is a non-planar membrane.

12. The continuous glucose monitoring system of claim 10 , wherein the first manufacturing parameter comprises a size of the membrane.

13. The continuous glucose monitoring system of claim 12 , wherein the size of the membrane is representative of a thickness of the membrane.

14. The continuous glucose monitoring system of claim 1 , wherein the first manufacturing parameter is an individualized manufacturing parameter.

15. The continuous glucose monitoring system of claim 14 , wherein the second manufacturing parameter is an individualized manufacturing parameter.

16. The continuous glucose monitoring system of claim 14 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the second manufacturing parameter is the same for each in vivo sensor in the batch.

17. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the first manufacturing parameter is the same for each in vivo sensor in the batch.

18. The continuous glucose monitoring system of claim 17 , wherein the second manufacturing parameter is an individualized manufacturing parameter.

19. The continuous glucose monitoring system of claim 17 , wherein the second manufacturing parameter is the same for each in vivo sensor in the batch.

20. The continuous glucose monitoring system of claim 1 , wherein the glucose monitoring system is configured for factory calibration such that it does not require user calibration or automated system calibration based on a reference value provided to the glucose monitoring system.

21. The continuous glucose monitoring system of claim 1 , wherein the glucose monitoring system is configured for user calibration.

22. The continuous glucose monitoring system of claim 1 , f 1 includes a first coefficient.

23. The continuous glucose monitoring system of claim 22 , wherein the first coefficient is empirically determined.

24. The continuous glucose monitoring system of claim 22 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the first coefficient is the same for each in vivo sensor in the batch.

25. The continuous glucose monitoring system of claim 22 , wherein the first coefficient is determined for the in vivo sensor on an individual basis.

26. The continuous glucose monitoring system of claim 22 , wherein f 2 includes a second coefficient.

27. The continuous glucose monitoring system of claim 26 , wherein the in vivo sensor is manufactured concurrently with a batch of other in vivo sensors, and the second coefficient is the same for each in vivo sensor in the batch.

28. The continuous glucose monitoring system of claim 26 , wherein the second coefficient is determined for the in vivo sensor on an individual basis.

29. The continuous glucose monitoring system of claim 1 , wherein the sensing characteristic is further determined base at least in part on f 3 (RMP c ), where f 3 is a third nonlinear function, and RMP C is a third manufacturing parameter.

30. The continuous glucose monitoring system of claim 1 , wherein the in vivo sensor comprising a sensing region comprising a sensing element, the sensing element being on a modified area of a sensor substrate having a liquid mobility characteristic different than an adjacent area of the sensor substrate.

31. A continuous glucose monitoring system, comprising:
an in vivo sensor configured to generate a signal associated with a glucose level of a user, the sensor including
a first portion configured to be positioned beneath a skin surface of the user and including a working electrode and a counter electrode,
a second portion configured to remain outside the user and including a first contact electrically coupled to the working electrode and a second contact electrically coupled to the counter electrode, and
at least one interferent-eliminating membrane layer disposed over the working electrode; and

a sensor control unit, wherein the first contact and the second contact of the in vivo sensor are each electrically coupled to the sensor control unit, and wherein the sensor control unit is programmed to process the generated signal from the in vivo sensor to generate a processed result that is representative of a glucose level of the user using calibration information, wherein the calibration information comprises a sensing characteristic of the in vivo sensor, and wherein the sensing characteristic is determined based at least in part on f 1 (RMP A ) and f 2 (RMP B );
wherein f 1

Assignees

• Abbott Diabetes Care Inc

Inventors

• Scott Steven
• Bennell Christopher J
• Bhogal Claire
• Cranfield Katie A
• Taub Marc B
• Winter Bree M
• Reynolds Owen D
• Babka Jean-Pierre
• Patel Dharmendra S
• Thomas Christopher A
• Hoss Udo
• Yahnke Mark S
• Khan Tahir S

Classifications

• A61B2562/12

  Manufacturing methods specially adapted for producing sensors for in-vivo measurements · CPC title

• A61B2560/0223

  of calibration, e.g. protocols for calibrating sensors · CPC title

• A61B5/14546

  for measuring analytes not otherwise provided for, e.g. ions, cytochromes · CPC title

• A61B5/14532

  for measuring glucose, e.g. by tissue impedance measurement · CPC title

• A61B5/14503

  invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence) · CPC title